Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relmapirazin - MediBeacon

Drug Profile

Relmapirazin - MediBeacon

Alternative Names: APC2; Lumitrace; MB 102; MP-3180; PP 2338

Latest Information Update: 09 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mallinckrodt Inc.
  • Developer MediBeacon
  • Class Diagnostic agents; Pyrazines; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute kidney injury; Kidney disorders
  • No development reported Crohn's disease

Most Recent Events

  • 30 Nov 2023 Hangzhou Zhongmei Huadong Pharmaceutical completes a phase III trial in Kidney disorders (Diagnosis) in China (IV) (NCT05943977)
  • 30 Nov 2023 MediBeacon reinitiates a phase III trial in Acute kidney injury and Kidney disorders (Diagnosis) in USA (IV) (NCT05777174)
  • 31 Aug 2023 MediBeacon suspends a phase III trial in Acute kidney injury and Kidney disorders (Diagnosis) in USA (IV) to submit an IDE amendment (NCT05777174)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top